Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 71Head & Neck 26Tumor-Agnostic 24Gastrointestinal 23Breast 16Genitourinary 8CNS 7Sarcoma 4Plasma cell 4Lymphoid 4Other hematologic neoplasm 3Dermatologic 3Other solid neoplasm 2Classical hematology 2Myeloid 1Gynecologic 1

Conditions

Rhabdomyosarcoma 1Neuroectodermal Tumors 1Chordoma 1Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation 1Advanced Solid Tumors 1

Interventions

Radiotherapy 215Cyclophosphamide 210Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Irinotecan 79Magnetic Resonance Spectroscopy 78pembrolizumab 75Radiation 66Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 44Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Afatinib × Sarcoma × Clear all
NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Amgen

Phase 1 Active not recruiting
610 enrolled
Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT03083678 2025-02-13

Afatinib in Locally Advanced and Metastatic Chordoma

Leiden University Medical Center

Phase 2 Completed
43 enrolled
Sarcoma

Chordoma

NCT02372006 2021-03-04

Trial of Afatinib in Pediatric Tumours

Boehringer Ingelheim

Phase 1/2 Completed
56 enrolled 23 charts
Sarcoma

Rhabdomyosarcoma, Neuroectodermal Tumors

NCT03810872 2019-01-22

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Universitair Ziekenhuis Brussel

Phase 2 Unknown
87 enrolled
SarcomaThoracic

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡